Tier 2 — strong

Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers

I Erlund, T Kosonen, G Alfthan, J Mäenpää, K Perttunen, J Kenraali, J Parantainen, A Aro
European journal of clinical pharmacology 2000 56(8):545

Bibliography

PubMed
PMID 11151743
DOI
10.1007/s002280000197
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignDouble-blind diet-controlled crossover pharmacokinetic study
ModelHuman intervention research
Sample16 healthy volunteers
InterventionQuercetin aglycone or rutin equivalent to 8, 20, or 50 mg quercetin
DurationSingle-dose periods with 32-hour sampling
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2000, this source examined forms, absorption and food sources. Design: Double-blind diet-controlled crossover pharmacokinetic study. Sample/model: 16 healthy volunteers. The exposure or intervention was Quercetin aglycone or rutin equivalent to 8, 20, or 50 mg quercetin. Follow-up or treatment period: Single-dose periods with 32-hour sampling.

Aglycone was absorbed earlier; rutin had more variable absorption. Overall exposure was similar in this experiment, and metabolites predominated.

Dose, analyte, and glycoside affect estimates. The findings do not support treating every quercetin formulation as pharmacokinetically interchangeable.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Forms: Dihydrate, Phytosome, Liposomal and Glycosides. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Aglycone was absorbed earlier; rutin had more variable absorption.
  • Overall exposure was similar in this experiment, and metabolites predominated.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Quercetin aglycone or rutin equivalent to 8, 20, or 50 mg quercetin; Single-dose periods with 32-hour sampling.

What this study can and cannot tell us

  • Dose, analyte, and glycoside affect estimates. The findings do not support treating every quercetin formulation as pharmacokinetically interchangeable.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies
Lu Liu et al. · Food chemistry · 2025
Tier 2
Microbiological and Pharmacokinetic Aspects of a Water-Soluble Quercetin 3-O-rutinoside, EubioQuercetin: A Direct Comparison With Quercetin in In Vitro and Human Clinical Studies
Naoto Yamaguchi et al. · Journal of food science · 2025
Tier 2
Comparative Pharmacokinetics and Safety of a Micellar Chrysin-Quercetin-Rutin Formulation: A Randomized Crossover Trial
Afoke Ibi et al. · Antioxidants (Basel, Switzerland) · 2025
Tier 2
Enhanced Bioavailability and Pharmacokinetics of a Natural Self-Emulsifying Reversible Hybrid-Hydrogel System of Quercetin: A Randomized Double-Blinded Comparative Crossover Study
Ashil Joseph et al. · ACS omega · 2022

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology